Top Lisinopril Brands to Consider for Quality and Affordability

When it comes to managing high blood pressure and heart conditions, lisinopril is a widely prescribed medication known for its effectiveness. Choosing the right brand of lisinopril can ensure quality and cost-effectiveness, as the pharmaceutical market offers several reliable options. Many patients and healthcare providers often recommend brands that have consistently demonstrated efficacy and safety. Some of the top brands for lisinopril include Zestril, Prinivil, and generic versions offered by renowned pharmaceutical companies. For a detailed list and comparison of these and other trusted brands, please see the information below.

Illustration of lisinopril

Best brands of lisinopril in 2025

Zestril

Zestril, produced by AstraZeneca, is a highly regarded brand of lisinopril, known for its consistent quality and reliability. It is available in various strengths, making it a versatile option for personalized treatment plans. Zestril has been proven to effectively control blood pressure and improve cardiovascular outcomes, contributing to the growth of the lisinopril market, which is expected to reach USD 2.3 billion by 2032 with a CAGR of 4.8% from 2024 to 2032. The brand's effectiveness is a key factor in the market's expansion, driven by the increasing prevalence of hypertension and cardiovascular diseases. Zestril's reputation as a trusted brand in the pharmaceutical industry further solidifies its position in the market. For more detailed insights, read The Ultimate Guide to Lisinopril Brand Names.

Prinivil

Prinivil, manufactured by Merck, is a highly regarded brand of lisinopril, known for its effectiveness in lowering blood pressure and reducing the risk of cardiovascular events. It is widely used and has been extensively studied, making it a trusted choice among healthcare professionals. Prinivil is available in various dosage strengths, allowing for personalized treatment plans. The global lisinopril market, which includes Prinivil, is expected to grow from $1.66 billion in 2023 to $2.26 billion by 2028 at a CAGR of 6.4%, driven by the rising prevalence of hypertension and cardiovascular diseases. For more detailed insights, explore the comprehensive market report.

Qbrelis

Qbrelis, developed by Silvergate Pharmaceuticals (now Azurity Pharmaceuticals, Inc.), is the first and only FDA-approved lisinopril oral solution, offering a significant advancement in the treatment of hypertension in adult and pediatric patients aged 6 and older, as well as adjunct therapy for heart failure and treatment of acute myocardial infarction in adults. Approved on July 29, 2016, Qbrelis provides a ready-to-use oral solution with consistent potency and stability, enabling weight-based dosing for children and benefiting adults who have trouble swallowing tablets. This formulation has contributed to the growing lisinopril market, which is expected to reach $1.76 billion in 2024 and $2.26 billion by 2028, with a CAGR of 6.4%. Qbrelis is available through an extensive network of pharmacies and mail order services, ensuring widespread accessibility. Its innovative delivery method aligns with market trends demanding patient-centric and cost-effective solutions. For further details, visit this FDA approval announcement.

Lisinopril Tablets by Teva

Lisinopril Tablets by Teva are a highly effective treatment for essential hypertension and heart failure, belonging to the class of angiotensin-converting enzyme (ACE) inhibitors. These tablets, available in strengths such as 5 mg, 10 mg, and 20 mg, work by relaxing blood vessels to lower blood pressure and improve blood flow to the heart. The market for lisinopril is projected to grow at a 4.8% CAGR from 2024 to 2032, with the market size valued at around USD 1.5 billion in 2023. Teva's lisinopril tablets are known for their oral long-acting properties and are often used concomitantly with other antihypertensive agents. The tablets are typically taken once daily and are available in various formulations, including a fixed-dose combination with hydrochlorothiazide. For detailed product information, you can refer to the Lisinopril Tablets datasheet.

Lisinopril Tablets by Aurobindo Pharma

Lisinopril Tablets by Aurobindo Pharma are a prominent offering in the market, known for their efficacy in treating hypertension, heart failure, and following myocardial infarction. Aurobindo Pharma, one of the largest generic pharmaceutical suppliers in the U.S. by prescription volume, manufactured approximately 41 billion units of various drugs in fiscal year 2023, including lisinopril. Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is available in 5 mg, 10 mg, and 20 mg tablets and is typically taken orally once daily. The growing prevalence of cardiovascular diseases, such as coronary artery disease which accounts for approximately 610,000 deaths annually in the U.S., underscores the importance of medications like lisinopril. Aurobindo's lisinopril tablets are part of a market projected to grow at a 4.8% CAGR from 2024 to 2032, reaching a value of USD 2.3 billion by 2032. For more detailed information, refer to the product information document.

Lisinopril Tablets by Lupin Pharmaceuticals

Lisinopril Tablets by Lupin Pharmaceuticals are a leading choice in the treatment of hypertension and heart failure, with the company receiving final FDA approval for its Lisinopril and Hydrochlorothiazide tablets in 2006. These tablets are available in various strengths, including 10mg/12.5mg, 20mg/12.5mg, and 20mg/25mg, and are recognized as the AB-rated generic equivalent of Merck & Co.'s Prinzide Tablets. Lupin's lisinopril market is expected to grow at a CAGR of 4.8% from 2024 to 2032, with the global lisinopril market valued at around USD 1.5 billion in 2023. The company's strong research focus and state-of-the-art R&D center contribute to its reputation as a top pharmaceutical company. Lupin's revenues for the financial year ended March 2006 were approximately USD 375 million. For more detailed information, you can refer to their Lisinopril and Hydrochlorothiazide tablets documentation.

Lisinopril Tablets by Sandoz

Lisinopril Sandoz, produced by Sandoz Pty Ltd, is a highly effective medication used to lower high blood pressure (hypertension), treat heart failure, and improve survival rates after a heart attack. It belongs to the class of angiotensin-converting enzyme (ACE) inhibitors, which work by relaxing blood vessels to improve blood flow and lower blood pressure. The usual starting dose for hypertension is 5-10 mg once daily, and for heart failure, it is 2.5 mg once daily, with doses adjustable based on patient response. Lisinopril Sandoz is available in 5 mg, 10 mg, and 20 mg tablets and should be taken at the same time each day for optimal effect. The lisinopril market, which includes Sandoz's product, is projected to grow at a 4.8% CAGR from 2024 to 2032, reflecting its continued importance in cardiovascular treatment. For further details, you can access additional information about Lisinopril Sandoz tablets.

Lisinopril Tablets by Dr. Reddy's Laboratories

Lisinopril tablets by Dr. Reddy's Laboratories are a highly regarded option, known for their efficacy in treating hypertension, heart failure, and post-myocardial infarction. With a market valued at USD 226.46 million in 2023 and expected to grow at a 4.3% CAGR until 2031, Dr. Reddy's Laboratories is a significant player in the lisinopril market. The company's strong performance in the generics segment, with a 36% year-over-year growth in North America and 17% in India for FY23, underscores its capability in producing high-quality generic medications. Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is prescribed for its ability to improve blood flow and reduce blood pressure, making it a crucial medication for cardiovascular health. Dr. Reddy's commitment to innovation and quality ensures that their lisinopril tablets meet stringent pharmaceutical standards. For more details, visit their official website.

Lisinopril Tablets by Mylan

Mylan's Lisinopril Tablets are a highly effective and widely prescribed medication for treating hypertension and heart failure, with lisinopril accounting for around 35% of overall ACE inhibitor prescriptions in the USA. Mylan's generic version of lisinopril is the equivalent of AstraZeneca's Zestril and Merck's Prinivil, and it was approved by the FDA in 2002. The drug is available in various strengths, including 5 mg, 10 mg, and 20 mg tablets. Lisinopril has been prescribed to approximately 87.4 million people in the USA as of 2019, highlighting its efficacy and cost-effectiveness. Mylan's commitment to quality and affordability makes their lisinopril tablets a preferred choice among healthcare professionals. For more detailed information, you can access the product monograph.

Lisinopril Tablets by Cipla

Lisinopril tablets, such as those produced by Cipla, are a cornerstone in the treatment of hypertension and heart failure, belonging to the class of angiotensin-converting enzyme (ACE) inhibitors. These tablets work by relaxing blood vessels, thereby lowering blood pressure and improving blood flow to the heart. The global lisinopril market, which includes Cipla's offerings, is projected to grow at a CAGR of 4.30% to 5.36% from 2023 to 2031-2032, with the market size expected to reach around USD 3.35 billion by 2032. Cipla's lisinopril tablets are available in various dosage strengths, such as 10mg and 20mg, and are widely distributed through hospital pharmacies, retail pharmacies, and online channels. The increasing prevalence of hypertension and other cardiovascular diseases drives the demand for these tablets. For more details, explore Cipla's lisinopril tablets.